Presentations & Posters

​First-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 triggers mesenchymal-to-epithelial transition in mesothelioma 

At AACR-Tri, George Naumov, Our COO presented our poster RSO-021, a First-in-class Covalent Inhibitor of Mitochondrial PRX3: From Bench to Bedside

Our Chief Science Officer, Brian Cunniff, presented "Characterization of Immune Cell Phenotypes in Patient Derived Malignant Pleural Effusion Treated with Thiostrepton"

AACR Annual Meeting 2024 San Diego, USA Brian Cunniff presented ​Molecular/Cellular Biology and Genetics- Cellular Stress Responses 1

Our Chief Scientist, Brian Cunniff, presented "Effects of RSO-021 on cytokine profiles of malignant pleural effusions from patients enrolled in the MITOPE phase 1/2 clinical trial "

RS Oncology successfully presented their first-in-human clinical trial poster at ESMO Congress 2022.